Botanix Pharmaceuticals

Unlocking the potential of synthetic cannabinoids

Pharmaceutical company leveraging the unique properties of synthetic cannabinoids with its Permetrex™ technology

Promising R&D, with a rapidly advancing pipeline of dermatology and antimicrobial products

World-class team with extensive cannabinoid drug development and commercialisation expertise

Evidence, first

Botanix Pharmaceuticals is a clinical stage synthetic cannabinoid pharmaceutical company with a targeted pipeline of dermatology and antimicrobial products. We have attracted a world-class team and significant capital to support the progression of our products. We are moving quickly, but never at the expense of our rigorous commitment to ethical research and development (R&D) and the highest clinical standards mandated by the US Food and Drug Administration (FDA). Our goal is to unlock the true potential of synthetic cannabinoids for people around the world, with an evidence-first approach.

Check out our latest news

“The Superbug Era” – ABC documentary

Addressing the pressing global emergency of antimicrobial resistance…

Australian medicinal cannabis revenue tipped to reach $200 million in 2021

Australian medicinal cannabis revenue is tipped to double this…

Rosacea Study Approval

Papulopustular rosacea is a highly visible and distressing chronic…

Progress Report for Australia’s First National AMR Strategy

The Australian Government has published the Final Progress Report…

Presentation: ASX Small and Mid-Cap Conference

Botanix Pharmaceuticals President and Executive Chairman, Vince…

ScoPo’s powerplays: Jazz Pharma’s $9.4b deal highlights pot plays

'A huge acquisition in the international medical cannabis sector…

Endpoints News | Jazz vaults into the cannabinoid field with $7.2B GW Pharma buyout

GW Pharma $GWPH, the UK biotech that caused a sensation of sorts…

Invest in innovation

Botanix Pharmaceuticals offers a compelling opportunity for investors who are interested in capitalising on the clinical potential of synthetic cannabinoids. Our clinical trials to date have highlighted the unique mechanism of action which drives synthetic cannabidiol to produce anti-inflammatory and antimicrobial effects. We are leveraging this evidence to inform the development of new pharmaceutical products, targeting some of the most underserved and lucrative segments of the global healthcare market. Already, we have one of the most advanced clinical pipelines for synthetic cannabinoids in the world.

New treatments, in demand

Botanix has generated strong scientific support for the anti-inflammatory and antimicrobial mechanisms of action of synthetic cannabinoids with application in the development of novel dermatology and bacteria fighting applications.

There have been no new chemical entities (NCE’s) in topical drugs approved for acne in more than two decades and resistance to available antibiotics remains a significant global issue, with no new classes of antibiotics approved in more than three decades. When bacteria survive exposure to antibiotics that would normally eliminate them, these surviving bacteria grow and spread resistance, leading to the emergence of ‘superbugs’. New treatments in dermatology and anti-microbials are needed now.

Botanix periodically runs clinical studies in Australia, New Zealand the USA. Share your details if you would like to learn more.

Sign up to receive our latest news.

Processing...
Thank you! Your subscription has been confirmed. You'll hear from us soon.
ErrorHere